Behandlung der chronischen Blepharokeratokonjunktivitis mit lokalen Kalzineurininhibitoren

Abstract

Topical calcineurin inhibitors (cyclosporin A 1%, FK506, pimecrolimus) can be useful for treating chronic blepharokeratoconjunctivitis in addition to lid hygiene and lubricants. This treatment leads to an improvement of dry eye symptoms and reduces inflammation.

Blepharokeratoconjunctivitis in childhood: corneal involvement and visual outcome

“…[3][4][5]36 On the other hand, topical CsA may be used for longer periods of time to control inflammation (at least 3 months to reach therapeutic effect), but with the inconvenience of high cost and low-tolerance profile. 37,38 CsA was used in 5 (11.1%) of our patients with active and severe corneal involvement for a mean time of 6.5 months, with three patients showing adequate control of inflammation. The other two patients stopped the medication owing to intolerance.…”

Molecular Diagnostics of Calcineurin-Related Pathologies

“…A large number of genes in endothelial cells, osteoblasts, chondrocytes, and osteoclasts have been linked to NFAT transcriptional control, suggesting a multifaceted role for the Cn/NFAT axis in bone remodeling and control of joint architecture (101,102 ). Topical CnIs, including the new agent voclosporin, show good results in treating several types of inflammatory eye disease (103,104 ). Cn is produced in various eye tissues, with the highest concentrations occurring in the retina, cornea, and optic nerve.…”

Chronische Blepharitis

“…Bei den verschiedenen Formen der Blepharitis kommt es zu Veränderungen der Lipidzusammensetzung des Tränenfilms. Sowohl Bakterien der Standortflora als auch andere Bakterien können die Lipide des Meibom-Drüsen-Sekretes hydrolysieren 16 . Durch proinflammatorische Zytokine und die Freisetzung von Lipasen und Cholesterinesterasen durch Standortbakterien kommt es zu entzündlichen Veränderungen im Bereich der Lidkanten.…”